Unknown

Dataset Information

0

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137.


ABSTRACT: Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical responses and confirmed that the immune system can significantly inhibit tumor progression. Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. CD137 (also known as 4-1BB) a member of the tumor necrosis factor (TNF) receptor superfamily, is an activation-induced T cell costimulator molecule. Growing evidence indicates that anti-CD137 monoclonal antibodies possess strong antitumor properties, the result of their powerful capability to activate CD8+ T cells, to produce interferon (IFN)-?, and to induce cytolytic markers. Combination therapy of anti-CD137 with other anticancer agents, such as radiation, has robust tumor-regressing abilities against nonimmunogenic or poorly immunogenic tumors. Of importance, targeting CD137 eliminates established tumors, and the fact that anti-CD137 therapy acts in concert with other anticancer agents and/or radiation therapy to eradicate nonimmunogenic and weakly immunogenic tumors is an additional benefit. Currently, BMS-663513, a humanized anti-CD137 antibody, is in clinical trials in patients with solid tumors, including melanoma, renal carcinoma, ovarian cancer, and B-cell malignancies. In this review, we discuss the basis of the therapeutic potential of targeting CD137 in cancer treatment, focusing in particular, on BMS-663513 as an immune costimulatory monoclonal antibody for melanoma immunotherapy.

SUBMITTER: Li SY 

PROVIDER: S-EPMC3776567 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137.

Li Shi-Yan SY   Liu Yizhen Y  

Clinical pharmacology : advances and applications 20130902 Suppl 1


Knowledge of how the immune system recognizes and attempts to control cancer growth and development has improved dramatically. The advent of immunotherapies for cancer has resulted in robust clinical responses and confirmed that the immune system can significantly inhibit tumor progression. Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. CD137 (also known as 4-1BB) a member of the tumor necrosis factor (TNF) receptor superfamily, is an activ  ...[more]

Similar Datasets

| S-EPMC7333812 | biostudies-literature
| S-EPMC5609554 | biostudies-literature
| S-EPMC5036540 | biostudies-literature
| S-EPMC8483511 | biostudies-literature
| S-EPMC6963985 | biostudies-literature
| S-EPMC3508064 | biostudies-literature
| S-EPMC6895894 | biostudies-literature
| S-EPMC7843650 | biostudies-literature
| S-EPMC5739564 | biostudies-literature
| S-EPMC7003380 | biostudies-literature